Infectious Disease Control

Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore

First drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy SINGAPORE, Dec. 22, 2023 /PRNewswire/ -- Singapore-headquartered Juniper Therapeutix , a science-led healthcare company focused on commerciali...

2023-12-22 07:00 2198

International Clinical Trial Results Released! Responding to the Virus Resurgence, Lianhua Qingwen Capsules Provide New Evidence

SINGAPORE, Dec. 21, 2023 /PRNewswire/ -- Recently, according to multiple reports from local Singaporean media, confirmed cases of COVID-19 are steadily increasing, with the average number of daily hospitalizations on the rise. The virus, once vigorously fought against, seems to be making a comeba...

2023-12-21 18:06 2084

BioSURE Pro Protective Nasal Spray from the UK: Block airborne viruses instantly for six hours with a Gentle Lavender Scent

HONG KONG, Dec. 15, 2023 /PRNewswire/ -- The weather was gradually cooling down, which means thatHong Kong is entering the winter influenza season. Recently, there has been a significant increase in Mycoplasma pneumoniae infections, the surveillance data from the Centre for Health Protection (CHP...

2023-12-15 20:21 2376

Tianlong Solution Facilitates the Prevention and Control of Livestock Diseases

XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- It was recently announced that Tianlong Technology complies with the requirements of Chinese Good Manufacturing Practices for animal drugs. This approval further ensures Tianlong's focus on standardized workflows in the development of animal products. ...

2023-12-15 19:23 1803

Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs

SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...

2023-12-14 17:00 3498

CU Medicine study published in The Lancet Infectious Diseases concludes that a novel oral microencapsulated live bacteria consortia (SIM01) alleviates long COVID symptoms

HONG KONG, Dec. 8, 2023 /PRNewswire/ -- A randomised, double-blind, placebo-controlled trial (RECOVERY STUDY) conducted by TheChinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and Microbiota I-Center (MagIC) showed that an oral microbiome microencapsulated formula (SIM01)...

2023-12-08 10:38 1773

GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC

–2023 Gilead Asia Pacific Rainbow Grant Funding Will Support 40 Projects In 2024-2025 To Reduce HIV Stigma And Improve Equity Across Asia Pacific – – Since 2018, The Gilead Asia Pacific Rainbow Grant Has Awarded Close To US$6 Million To 144 Community-Based Projects In The Region, Supporting 130 00...

2023-11-29 11:00 1597

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

GAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Or...

2023-11-28 19:00 1604

Ark Biopharmaceutical Receives IND Approval from NMPA for AK0610, a Respiratory Syncytial Virus Neutralizing Antibody

SHANGHAI, Nov. 23, 2023 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announces that it had received IND approval from National Medical Products Administration (NMPA) for a novel antibody drug AK0610. This antibody drug is bioengineered based on a neutralizing antibody origina...

2023-11-23 08:00 1978

TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug

Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that will be tested as part of Phase 2 trial The first participant has been dosed in this partially double-blind study to evaluate the safety and efficacy of what has the po...

2023-11-16 20:20 1234

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to la...

2023-11-13 18:31 1128

MicuRx announces poster presentation and participation in ID Week 2023 Conference

FOSTER CITY, Calif., Oct. 11, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announces that a poster on our preclinical product, MRX-6038, will be p...

2023-10-11 23:33 1432

KHB Becomes First Chinese Company to Obtain EU Class D IVDR Certification for Its Rapid Test HIV Colloidal Gold Diagnostic Kit

SHANGHAI, Oct. 11, 2023 /PRNewswire/ -- Shanghai Kehua Bio-engineering Co., Ltd ("KHB" or "the Company", Stock code: 002022.SZ),China's leading In Vitro Diagnostic (IVD) company has achieved a significant milestone by becoming the first Chinese company to obtain EU Clas...

2023-10-11 16:27 2046

Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre

TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO of Zimbabwe NBA, and Dr.Yang Yili, International Centre for Genetic Engineering and Biotechnology China Regional Research Centre(ICGEB), visited Recbio. Dr. SAVADYE and his team conducted an on-the-s...

2023-10-10 13:54 3815

Agilent and Sarawak Infectious Disease Centre Partner to Boost Neglected Tropical Diseases Research in East Malaysia

KUALA LUMPUR, Malaysia, Oct. 6, 2023 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE:...

2023-10-06 13:26 2722

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

* This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. * Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid * Fin...

2023-10-04 04:25 1830

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally

The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless. BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese R...

2023-10-02 15:00 1569

Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients

SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the T...

2023-09-28 07:38 1636

Global Times: China-Africa medical cooperation broadens under BRI

BEIJING, Sept. 4, 2023 /PRNewswire/ -- Tesfaye Hailemicheal and his colleagues have settled in the new headquarters of the Africa Centers for Disease Control and Prevention (Africa CDC) for over six months now. Hailemicheal still finds himself drawn to the meeting room across from his office. Fro...

2023-09-04 08:43 1582

Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress

TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted pr...

2023-08-28 11:08 2498
12345 ... 78